$1.30
-0.14-9.72%
Last update: Nov 12, 12:47 PM
MetaVia Inc (MTVA) Stock Price, Quote, News & History
MTVANASDAQ
MetaVia reports positive Phase 1 data showing that once-weekly DA-1726 significantly reduces serum uric acid and liver fat.
You can purchase shares of MetaVia (NASDAQ:MTVA) through any online brokerage.
Other companies in MetaVia’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
MetaVia has a consensus price target of $61.67.
The stock price for MetaVia (NASDAQ: MTVA) is $1.3 last updated November 12, 2026 at 12:47 PM EST.
There are no upcoming dividends for MetaVia.
MetaVia does not have any upcoming earnings scheduled.
There is no upcoming split for MetaVia.
MetaVia is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
MetaVia Inc is a clinical-stage biotechnology company focused on developing treatments for liver-related cardiometabolic diseases. Its product pipeline includes DA-1726, an oxyntomodulin analogue that acts as a dual GLP-1 and glucagon receptor...
